Stratos Wealth Partners LTD. Sells 964 Shares of CVS Health Corporation $CVS

Stratos Wealth Partners LTD. trimmed its position in shares of CVS Health Corporation (NYSE:CVS) by 3.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,113 shares of the pharmacy operator’s stock after selling 964 shares during the period. Stratos Wealth Partners LTD.’s holdings in CVS Health were worth $1,801,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Hazlett Burt & Watson Inc. lifted its stake in shares of CVS Health by 10.9% in the second quarter. Hazlett Burt & Watson Inc. now owns 1,682 shares of the pharmacy operator’s stock valued at $117,000 after buying an additional 165 shares during the period. Essex Financial Services Inc. lifted its stake in shares of CVS Health by 0.8% in the first quarter. Essex Financial Services Inc. now owns 20,705 shares of the pharmacy operator’s stock valued at $1,403,000 after buying an additional 166 shares during the period. Williams Financial LLC lifted its stake in shares of CVS Health by 2.5% in the second quarter. Williams Financial LLC now owns 6,923 shares of the pharmacy operator’s stock valued at $478,000 after buying an additional 167 shares during the period. Hemington Wealth Management lifted its stake in shares of CVS Health by 33.7% in the first quarter. Hemington Wealth Management now owns 682 shares of the pharmacy operator’s stock valued at $46,000 after buying an additional 172 shares during the period. Finally, Sumitomo Life Insurance Co. lifted its stake in shares of CVS Health by 1.0% in the first quarter. Sumitomo Life Insurance Co. now owns 17,114 shares of the pharmacy operator’s stock valued at $1,159,000 after buying an additional 174 shares during the period. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Performance

NYSE CVS opened at $82.47 on Tuesday. The firm has a market cap of $104.59 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 0.91 and a beta of 0.60. The company has a 50 day moving average of $74.35 and a 200-day moving average of $68.25. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $82.88.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.35. The company had revenue of $98.92 billion during the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be issued a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, October 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. CVS Health’s dividend payout ratio (DPR) is presently 74.30%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CVS shares. Sanford C. Bernstein increased their target price on shares of CVS Health from $72.00 to $77.00 and gave the company a “market perform” rating in a research note on Friday, September 5th. Mizuho increased their target price on shares of CVS Health from $76.00 to $88.00 and gave the company an “outperform” rating in a research note on Thursday, October 9th. Leerink Partners raised their price target on shares of CVS Health from $86.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Wells Fargo & Company raised their price target on shares of CVS Health from $84.00 to $103.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 7th. Finally, Zacks Research cut shares of CVS Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $82.57.

Insider Buying and Selling at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the sale, the director owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.22% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.